potentially serious consequences of failure of therapy, particularly in well-controlled patients; potential for adverse events and variability of response to AEDs; need for careful titration and dosing of AEDs and susceptibility of some patients to develop problems, even with small changes in drug levels; bioequivalence, as defined by regulatory bodies, may not correspond to therapeutic equivalence for AEDs, because of the permitted range of bioavailability for generics, evaluation methods that use small numbers of relatively young healthy volunteers and individual variation; potential for problems from poor continuity of supply; cost savings may be outweighed by the cost of adverse consequences; potential medico-legal consequences in patients who did not give informed consent to switching of AEDs.
Introduction
Healthcare systems in the developed world are under pressure from increasing numbers of elderly people, increasing patient expectations, and costly advances in healthcare technology including new medicines. Without the economic growth to meet these increasing demands, most healthcare systems have taken steps to limit cost escalation, including the introduction of health technology assessment agencies to determine the cost-effectiveness of new therapies, pricing controls such as referencing to the cost of treatments in other countries, and encouraging the use of cheaper generic medicines instead of branded products. While the economic need to limit healthcare costs is not questioned, it is important to ensure that patient health is not compromised. This review aims to explore potential problems with generic substitution of antiepileptic drugs (AEDs).
Generic prescribing
The innovations from research-based pharmaceutical companies are protected from copying by patents that typically last 20 years from the first filing of the new chemical entity. As all the development work and clinical trials on a new chemical entity is conducted by the innovator in order to gain the initial marketing authorisation, the generic manufacturer has only to demonstrate bioequivalence of the generic product and the branded product to gain a product licence. This is the main reason why generic products can be priced well below the price of innovative products. 1 Since generics are the same chemical entity as the branded product, healthcare payers and many physicians expect that generic products can be used interchangeably with each other and the original product. 2 Consequently, generic prescribing is widely advocated as a measure of cost containment. Physicians are routinely encouraged by healthcare management to prescribe products generically, 3 while computer prescribing systems often automatically convert brand names into generic versions.
As a consequence, the proportion of prescriptions written generically has increased markedly over recent years. 4 In some markets (e.g. UK), generic products can only be dispensed against prescriptions that are written generically--substitution of a generic product for a prescription written as the brand name is not permitted. However, in many other markets (e.g. Canada), generic substitution (i.e. dispensing of a generic version if one is available, even if the physician used the brand name on the prescription) is allowed or mandated. If the physicians do not want the generic product to be given, they may be able to indicate this on the prescription or by filling in other exemption forms. In some countries, if patients insist on receiving the branded product, they are expected to pay the difference in cost over the lowest price generic product.
Although healthcare systems tend to favour the use of generic products because of the savings in cost of medicines, there are a number of potential disadvantages to the use of generic products (Table 1) . 3, 5 In the majority of therapeutic areas, these disadvantages are irrelevant or minor in comparison to the economic benefits. However, many 166 P. Crawford et al. Table 1 Disadvantages of using a generic product 3, 5 Rate and extent of absorption (bioavailability) may differ between generics and branded products Generic names are not as easy to remember, spell or pronounce as branded names Generic products usually differ in appearance (e.g. colour, shape) from the brand and from one another, causing confusion and anxiety for patients Excipients and colorants used in generic products may differ from the brand--although these agents are intended to be inert, they can cause problems in some patients If problems occur with a generic product, it may be difficult to identify the manufacturer or supplier, once it has been dispensed, and the innovator company may be the recipient of the pharmacovigilance report rather than the generic company Use of generic products may inhibit research and innovation
The limited evidence (mainly case reports with some pharmacokinetic studies) appears to support these concerns for older AEDs. As a result, restrictions on use of specific generic AEDs are in place in some countries and recommended by some lay epilepsy organisations.
As more AEDs lose patent protection, it is important to examine the question of whether generic substitution may pose problems for patients with epilepsy, and whether there should be safeguards to ensure that both physician and patient are informed when generic substitution occurs. # 2006 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
healthcare systems recognise that changing the supplier of medicines could compromise care of patients with certain conditions. 6 Physicians are advised to prescribe these products by brand name, and such products are exempt from generic substitution. A number of experts and professional bodies have recommended caution with generic substitution of drugs required for epilepsy.
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Search strategy
In order to review the issue of generic substitution of antiepileptic drugs, a systematic literature search was conducted. A broad search strategy was adopted that included the generic names of AEDs, together with terms relevant to generic substitution such as bioequivalence, bioinequivalence, bioavailability, pharmacokinetics and narrow therapeutic index. Desktop databases were searched, including Medline, Current Contents and International Pharmaceutical Abstracts. Approximately 1470 references were identified and approximately 70 relevant articles were selected as these were the only ones which related to epilepsy and generic prescribing of antiepileptic drugs.
It was of interest to note that very few articles described randomised controlled clinical trials comparing generic and branded products. The majority of articles consisted of case reports, letters discussing case reports, or opinion pieces without presentation of new data. The paucity of evidence means that this review can only highlight the issues and need for more carefully conducted studies.
Issues of concern
Reviewing the literature, issues of concern about the use of generic AEDs centred around a number of themes (Table 2) , each of which is discussed in more detail.
Characteristics of epilepsy
Epilepsy is a chronic disorder that often requires lifelong treatment. Avoidance of seizures is the primary goal, while keeping adverse effects to a minimum. 10 When long-term remission has been achieved, it becomes important to avoid even a single breakthrough seizure. Many papers highlighted the importance of this issue. 5, 7, 9, [11] [12] [13] [14] [15] [16] [17] [18] [19] Just one seizure after a period of control can have major implications at the social level (e.g. loss of driving licence, loss of employment) and at the personal level (e.g. risk of injury, loss of self-esteem). There may even be fatal consequences--the risk of death in patients with uncontrolled seizures is higher than in seizure-free patients. 20 There is, therefore, considerably more at stake when treating epilepsy than with many other conditions, such as peptic ulcer, when any slight loss of efficacy on changing product would be expected to have limited consequences.
Characteristics of antiepileptic drugs
There is a limited armamentarium of treatments for epilepsy, with drugs such as carbamazepine, sodium valproate and phenytoin forming the mainstay of therapy. The narrow therapeutic index of these AEDs necessitates some monitoring of serum drug concentrations.
Many AEDs are considered to be treatments with a narrow therapeutic index (i.e. only a small relative difference in dose between therapeutic and toxic effects). A narrow therapeutic index implies that slight variations in drug absorption could result in significant negative health outcomes. 21 The FDA considers a drug to have a narrow therapeutic index if:
there is less than a two-fold difference between the minimum toxic concentration and the minimum effective concentration; safe and effective use requires careful titration and patient monitoring. 8, 22 Narrow therapeutic index has also been used to describe medications that practitioners consider may present difficulties with generic substitution. 8 
Publications concerning AEDs have focused on
Are there potential problems with generic substitution of antiepileptic drugs AEDs that have a narrow therapeutic index (Table 3) . 8, 14, 15, 23 With all AEDs, there is wide variation in therapeutic dose among individuals. To ensure that the optimal dose of AED is used and to avoid toxicity, dosage is usually adjusted over a considerable period of time, according to the response of the individual. 10 Even AEDs with low toxicity and with a wide therapeutic index, such as lamotrigine, require titration to the optimal dose. 24 
Complexity of management regimens
Establishing seizure control can be difficult, and a number of AEDs may have to be tried at various doses to identify which treatment is most effective and tolerable. If adequate control of seizures is not achieved with a tolerable dose of one or two AEDs in sequential monotherapy, then other AEDs are often added as adjunctive therapy, again with titration according to the therapeutic response. As a result, many patients with epilepsy are on a daily regimen of multiple treatments that has been carefully adjusted to obtain the optimal response. Many AEDs induce hepatic microsomal enzymes, increasing the rate of metabolism of concomitant drugs. This further complicates the dosage of AEDs in patients receiving polypharmacy, adding to concerns about the potential for adverse consequences if any aspect of this finally balanced therapy is inadvertently disturbed. Consequently, there is considerable reluctance from physicians and patients to change therapeutic agents in some patients, particularly once stability has been achieved.
5,12,23
Bioequivalence versus therapeutic equivalence
There are strict regulations covering the licensing of generic products, in order to give physicians and patients confidence that they are equivalent to branded products. In most countries, generic products must have the same dose and form as the brand. In USA, Canada and other developed countries, generic products also have to demonstrate equivalent bioavailability (similar blood concentration profile over time) to the brand in order to obtain a product licence ( Table 4 ). The excipients and manufacturing processes for generic products can differ from the innovator product. This is why there may be differences in the appearance, taste and shelf life of generic and branded products. 24 Furthermore, the salt or ester of the active ingredient may also sometimes differ between branded and generic products. 25 In the majority of therapeutic areas, differences within the permitted range have negligible effects, so that equivalent bioavailability indicates bioequivalence (i.e. a similar effect) in the patient. 5 Indeed, bioavailability is considered by licensing authorities to be a demonstration of bioequivalence. However, commentators have noted that bioequivalence implies but does not guarantee that a drug will have the same therapeutic and adverse effects as the reference drug. 5, 24 Furthermore, despite the lack of specific regulations concerning the excipients in a generic formulation, these substances cannot be considered inactive or inert molecules, as different salts of the same active drug can have distinct chemical and biological properties. 
Permitted range of bioavailability
If the bioavailability of all approved products were plotted, the branded product would be in the middle of the distribution. 8 However, once a number of generic products are on the market, patients may be switched from one generic to another and possibly from one that has bioavailability at the top of the acceptable range to one that is at the opposite end of the range, increasing the potential for clinical problems. Many clinicians have raised concerns about the range of bioavailability that is permitted within the definition of bioequivalence. 2, 7, 12, 23, 32, 33 Evaluation of bioequivalence Bioequivalence studies are usually carried out with single doses on small numbers of healthy volunteers (usually young adults) who are not receiving other therapies. This is done in order to eliminate factors (such as the presence of a disease state) that may cause variations in the results. In the clinical situation, patients with epilepsy often receive multiple drugs. Many patients are likely to be older or younger than the adults used in standard tests, with consequent differences in drug handling characteristics. Some commentators have raised concerns about the accepted methods for evaluating bioequivalence. 2, 5, 32, 33 Individual variation Another important concern emerging in the literature is the considerable variation in response among individuals. 2, 9, 19, 26, 34 The evaluation of bioequivalence in a population of patients with epilepsy is not the same as establishing bioequivalence for an individual patient with epilepsy. It is well known that patients with epilepsy respond to AEDs in different ways, so that individual titration of doses is required. As with other concerns, there is little specific concrete supportive evidence in the literature. However, the American Academy of Neurology 9 noted that the ratio of generic to branded bioavailability in individual subjects reported to the FDA varied from 74% to 142%.
Continuity of supply
Another theme that emerges from the literature is concern over continuity of supply. 2, 8, 14 In general, commentators are not against generic AEDs per se. Rather the concern expressed is over the potential consequences of having multiple suppliers of a product. Although patients may receive a generic AED as the first treatment following diagnosis, more commonly, patients are switched to a generic product during maintenance therapy. 8 Regulatory authorities have recognised that the issue of bioequivalence is different for these two patient populations. In the USA, the FDA has used the term prescribability to describe the use of a generic as first therapy, and the term switchability for the use of a generic in a patient already established on therapy. 8 The rules on bioequivalence were primarily designed to address the need for prescribability. 8 It should make little difference to a patient if the initial titration of therapy is with a specific generic product. However, a patient stabilised on one AED may be at risk of that control being lost if the prescription is changed to a formulation from a different manufacturer. When subsequent prescriptions for the maintenance therapy are filled, these stabilised patients often receive a generic product from a different supplier.
Once a number of generic products are on the market, pharmacists may change their supplier according to price and availability. It has been noted by pharmacists that the lack of consistency in supply is the main problem they experience with generics. 35 Furthermore, patients cannot usually identify the source of a generic product (i.e. manufacturer or supplier) once the product has been dispensed so they may be unaware of such a change, 3 unless the products differ significantly in appearance.
Economic value
Formulary committees, health policy makers, consumer groups and others may see the increased use of generic products as an important tool in the battle to control healthcare costs. 8 In Italy, savings in excess of 25 million were made in 2002 as a result of the introduction of generic drugs. 1 Clearly, there is a big incentive to cut prescribing costs, and use of generic drugs can help. However, it is important to ensure that the acquisition cost of the generic product compared with the brand is not the only cost considered. The true cost of generic prescribing must also include the cost of additional visits to a physician or the hospital if the substitution causes problems, and the cost of treatment failure, if a seizure occurs. In the literature, many commentators note that the cost of one breakthrough seizure in a previously stable patient is so high that it could offset the savings from generics. 9, 12, 20, 27, 23, 32, 34, [36] [37] [38] [39] Legal situation and informed consent Some commentators express concern about the medico-legal situation, if adverse consequences arise from generic substitution. 2, 8, 9, 23, 24, 40 This issue is also complicated by the concept of informed consent. The question arises of legal responsibility if a breakthrough seizure occurs when the medication a patient has previously received is changed for another, considered by the regulatory authorities to be equivalent, without the informed consent of the patient (or the physician). While informed consent is a prerequisite to inclusion in clinical studies, it is not a legal obligation for switching preparations. It was noted that patients do not reap any direct benefit from generic substitution unless they are paying for their medication directly, though they bear the burden if any problems result. In a study of patients and neurologists, the majority of both groups were illinformed about generic AEDs, 24 implying that informed consent is not currently achieved. In another survey of physicians attending meetings on neurology and on epilepsy, over 80% of respondents were uncomfortable with patients receiving multiple formulations of generic carbamazepine. 40 
Clinical experience
The literature review identified anecdotal reports of problems arising from generic substitution of AEDs. Many consisted of case reports of individuals experiencing adverse events (breakthrough seizures or toxicity) on switching from branded AED to generic.
14,33,39,41-43 Inevitably, such reports do not mention the majority of patients who switched without problem, though such studies may support concerns about individual variation in response being inadequately addressed under current regulations. Furthermore, it is often difficult to prove that a particular adverse event is definitely associated with generic substitution. Case reports of problems arising before the introduction of regulations on bioequivalence are unlikely to be of relevance to generic prescribing today. The literature review also identified some crossover studies to investigate pharmacokinetic differences between generic and branded products. 28, [44] [45] [46] [47] [48] [49] [50] One study of patients treated with carbamazepine, valproate or phenytoin found that 18.7% of respondents experienced a switch in medication supplier in the previous 2 years, and of these, 10.8% perceived problems after the switch that were validated by their GP. 12 In another retrospective survey of 81 patients, 14% reported problems when switching from a brand to a generic product. 24 A postal survey of 6420 neurologists found that the majority of the 301 respondents reported problems with breakthrough seizures (68%) and/or increased side-effects (56%) in at least one patient with epilepsy switched from branded to generic AED. 27 Problems were also reported with switching between generic AEDs (33% reported breakthrough seizures in at least one patient and 27% reported tolerability problems). Nearly half of the neurologists reporting these problems (47%) stated that two to four patients were affected in the past year, with over a quarter (28%) reporting breakthrough seizures and/or tolerability problems with generic AEDs in five or more patients, suggesting that considerable patient morbidity occurred. As a consequence, neurologists reported the need for additional consultations (72% reported additional phone consultations, 63% reported additional office visits, 49% reported emergency room visits and 18% reported hospital admissions). The impact on the patient was also noted, with 29% reporting that the patient missed work, and 9% reporting patient injury as a consequence of the switched AED. Taking into account the additional costs arising, the author concluded that the results challenged the premise that generic substitution of AEDs is cost-effective.
The majority of studies reporting clinical experience identified in the literature search focussed on carbamazepine, phenytoin and valproate.
Experience with generic substitution of carbamazepine
Carbamazepine has very low water solubility and a narrow therapeutic range, two qualities that increase the likelihood that generic drugs will show therapeutic differences in the clinical situation, even if they are considered bioequivalent. 40 A number of studies have shown that there are considerable variations in the pharmacokinetic characteristics of different generic carbamazepine formulations, though other studies have found few such differences (Table 5) . One study, initiated by the FDA, found that three generic formulations were absorbed significantly more rapidly than the innovator brand. 44 However, the authors concluded that these differences would be unlikely to have clinical effects, and that the generic formulations were comparable to one another.
Of interest is the finding that, although statistical similarity between products from different manufacturers could be demonstrated in a group as a whole, in one study of 40 patients, a quarter had variation in AUC greater than 20%, with differences as high as 53%. 33 A review of the literature concluded that the relative bioavailability (i.e. AUC Cross over study in 21 volunteers No differences in rate or extent of absorption of two sustained release formulations of carabamazepine 54 Study on 18 healthy volunteers Examined in vitro pharmacokinetic characteristics of three generics and Tegretol and compared with side effect profile. Main side effect (dizziness) related to variation in rate of absorption generic drug/AUC brand name drug) varied widely both between generic formulations and between batches within the same formulation. 34 Individual variations in pharmacokinetic parameters may explain the case reports of breakthrough seizures on generic substitution (Table 6) . Indeed, it has been estimated that over 20% of cases of loss of efficacy with carbamazepine may be traced to lowering of serum levels following a switch to a generic product. 55 There have also been reports of increased tolerability problems with generic substitution. 34 Following the replacement of the innovator brand, Tegretol, with generic products, there have been reports of a higher incidence of neurological side effects and skin rash. 34 The potential risks to patients from substituting Tegretol result in few cost savings, 34 estimated at less than the additional costs incurred as a result. 39 In the case of a child hospitalised because of toxicity arising from substitution of generic carbamazepine for the brand, the cost of $8000 was noted to greatly overshadow the $3.25 weekly savings from generic substitution, 33 though the frequency of such adverse consequences was not assessed.
Experience with generic substitution of phenytoin
Phenytoin has low water solubility, narrow therapeutic range and nonlinear kinetics--all risk factors for potential problems with generic substitution. 23 Many papers in the 1960s and 1970s reported differences in pharmacokinetics between the innovator brand (Dilantin) and generic phenytoin, [56] [57] [58] [59] [60] [61] [62] and clinical problems from breakthrough seizures and toxicity. [63] [64] [65] Many of these reports originated in Australia and were caused by a change in excipient. 31 More recent studies on bioequivalence have reported differences in pharmacokinetic parameters between generic phenytoin and the innovator brand, 30, 66, 67 though some of these differences were small and considered unlikely to have clinical consequences. 29, 68 Differences in the content of phenytoin between capsules of generic and branded preparations, rather than differences in the pharmacokinetics per se, have also been reported. 31 Differences in pharmacokinetic parameters between branded and generic formulations have been reported in Chinese subjects 69 and when taken with food, 16 which could have clinical implications.
Experience with generic substitution of valproate
Valproate has a relatively narrow therapeutic range and nonlinear pharmacokinetics--both risk factors for difficulties with generic substitution. 23 In an open study, 64 patients with seizure disorders and mental retardation were randomly assigned to generic valproate, or continued to receive the branded innovator product (Depakene) for 4 weeks, and were then switched to the other therapy. 70 There were no significant changes in blood levels of the products, or in seizure frequency, though the same manufacturer produced the capsules for both the branded and the generic companies. The authors concluded that switching from the branded product (priced at $94.23 for 100 capsules of 250 mg) to the generic product (priced at $7.39) would result in considerable cost savings.
However, there have also been at least two reports of patients experiencing problems when switching between the branded and generic product. In one case, a 19 year old woman experienced 172 P. Crawford et al. while in the other report, a 44 year old woman suffered gastrointestinal side effects after switching from an enteric-coated branded tablet to a generic formulation.
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Implications
Although the evidence is limited, the substantial concerns expressed about potential problems arising from uncontrolled switching of patients between older AEDs from different manufacturers appear to have some grounding in clinical experience. These findings suggest that, although mean values for bioavailability for licensed generic products are within the range specified by the authorities, variability in response means that some individuals (particularly those with well-controlled epilepsy) may be placed at unjustified risk by generic substitution. 9 The current recommendations of the American Academy of Neurology 9 are summarised in Table 7 , though these are under review.
It has been suggested that generic substitution is not allowed where there are special factors that could result in therapeutic differences, even if products are considered by regulatory authorities as bioequivalent (Table 8) .
In recognition of these issues, the FDA has listed carbamazepine, phenytoin and valproate as products with restrictions on generic substitution. 8 In Spain, carbamazepine and gabapentin are excluded from a reference list, despite generics being available, indicating that pharmacists are not expected to substitute the generic for the branded product. In Germany, a law for reduction of drug related costs in healthcare became effective in February 2002, which allows pharmacists to substitute a generic product instead of the brand, unless explicitly prohibited by the physician. However, the German Section of the International League Against Epilepsy published a statement against this approach for AEDs (Table 9) , 7 and AEDs were not included in the final list of drugs considered as suitable for substitution. In Denmark, some AEDs containing oxcarbamazepine are exempt from generic substitution because of bioequivalence problems, while Finland has exempt all AEDs from substitution. South Africa recommends that cabamazepine and phenytoin are not substituted, while noting that it is also not advisable for any medicines with narrow therapeutic range, erratic intra/inter patient responses, dosage forms likely to result in bioavailability problems (e.g. delayed release) and for use in critically ill, paediatric or geriatric populations. In the UK, brand name prescribing for AEDs is recommended.
As other AEDs lose patent protection, it is important to ensure that patients, pharmacists, prescribers and decision-makers are all aware of the issues to consider. Although newer AEDs, such as lamotrigine, gabapentin, topiramate and levetriacetam, are not considered to have a narrow therapeutic range like carbamazepine or valproate, some of the issues of concern still apply. 24 Like the older AEDs, they require individual titration, and the consequences of a breakthrough seizure are the same, regardless of the therapy that failed. In the light of the concerns expressed and clinical experience with older AEDs, more evidence is required before generic substitution of other AEDs is permitted. This has recently been recognised in Sweden, which has added gabapentin to the list of products like carbamazepine and valproate already exempt from mandatory generic substitution. Furthermore, the legal situation should be clarified, with responsibilities assigned for ensuring patients and physicians are informed.
Conclusions
Generic prescribing is an important tool in ensuring effective use of limited healthcare resources. While this approach is widely supported, the concerns about uncontrolled switching of AED manufacturers expressed by physicians caring for patients with epilepsy must be noted: potentially serious consequences of any failure of therapy; potential for adverse events and variability of response to certain AEDs in some individuals; need for careful titration of AEDs and complex management regimens that have a high potential for disruption if any component is changed in certain patients; bioequivalence, as defined in regulations, does not always correspond to therapeutic equivalence for AEDs, because of the permitted range, evaluation methods and individual variation; high potential for repeated switching of AEDs from different manufacturers due to poor continuity of supply and pharmacists' cost concerns; savings made from generic prescribing of AEDs may be outweighed by the cost of adverse consequences in some patients; potential medico-legal consequences if adverse consequences arise in a patient who did not give informed consent to switching of AED manufacturer.
Clinical experience appears to support these concerns, which has resulted in restrictions on use of specific generic AEDs in some countries. Caution is advised on generic substitution for newly off-patent AEDs. The challenge is to gather more data to identify groups and drugs (especially among the newer AEDs) which pose the highest risk and to determine whether there are other factors, apart from bioavailability variations, that account for the lack of therapeutic equivalence among different preparations in some individuals. Studies to address these issues comprehensively with all of the newer agents are unlikely to be conducted. Therefore it is prudent for patients, neurologists and pharmacists to be aware of the issues and to approve generic prescribing of AEDs for certain high-risk patients prior to it being instituted.
